Table 5.
Clinical data and biochemical results for survivors and non-survivors COVID-19 patients.
| Hospitalized patients | Non-Survivors | Survivors | p |
|---|---|---|---|
| N, % | 20 (10.1%) | 179 (89.9%) | < 0.001 |
| Age (years) | 73.0 ± 17.1 | 57.3 ± 15.4 | 0.029 |
| DM (n, %) | 0/20 (0.0) | 27/179 (15.1) | < 0.001 |
| HT (n, %) | 12/20 (60.0) | 63/179 (35.2) | < 0.001 |
| Obesity (n, %) | 2/20 (10.0) | 17/179 (9.5) | 0.810 |
| CKD (n, %) | 1/20 (5.0) | 14/179 (7.8) | 0.653 |
| HF (n, %) | 0/20 (0.0) | 1/179 (0.6) | 0.728 |
| AKI (n, %) | 5/20 (25.0) | 10/179 (5.6) | 0.002 |
| ICU (n, %) | 6/20 (30.0) | 18/179 (10.1) | 0.009 |
| Significant parameters | |||
| Male (n, %) | 17/20 (85.0) | 104/179 (58.1) | 0.019 |
| Urine blood presence (n, %) | 11/20 (55.0) | 24/179 (13.4) | < 0.001 |
| Urine protein presence (n, %) | 17/20 (85.0) | 83/179 (46.4) | 0.001 |
| D-Dimer (ng/mL) | 461 (770) | 229 (224) | 0.039 |
| Serum Albumin (g/L) | 32.6 ± 4.7 | 36.7 ± 3.7 | 0.003 |
| LDH (U/L) | 418 (186) | 308 (143) | 0.003 |
| CK (U/L) | 192 (163) | 59 (77) | 0.004 |
| CRP (mg/dL) | 14.71 (12.71) | 6.32 (9.34) | 0.007 |
Quantitative variables were described by mean ± standard deviation or median (IQR); DM, Diabetes; HT, Hypertension; CKD, Chronic kidney disease; HF, heart failure; ICU, Intensive Care Unit; AKI, Acute Kidney Injury; LDH, lactate dehydrogenase; CK, creatine kinase; CRP, C-reactive protein.